AstraZeneca PLC
AZN · NASDAQ
9/30/2025 | 6/30/2025 | 3/30/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $15,191,000 | $14,457,000 | $13,588,000 | $14,891,000 |
| % Growth | 5.1% | 6.4% | -8.8% | – |
| Cost of Goods Sold | $2,862,000 | $2,473,000 | $2,241,000 | $2,725,000 |
| Gross Profit | $12,329,000 | $11,984,000 | $11,347,000 | $12,166,000 |
| % Margin | 81.2% | 82.9% | 83.5% | 81.7% |
| R&D Expenses | $3,663,000 | $3,548,000 | $3,159,000 | $4,677,000 |
| G&A Expenses | $4,972,000 | $4,864,000 | $4,492,000 | $5,410,000 |
| SG&A Expenses | $5,120,000 | $5,007,000 | $4,627,000 | $5,553,000 |
| Sales & Mktg Exp. | $148,000 | $143,000 | $135,000 | $143,000 |
| Other Operating Expenses | -$37,000 | -$79,000 | -$113,000 | -$100,000 |
| Operating Expenses | $8,746,000 | $8,476,000 | $7,673,000 | $10,130,000 |
| Operating Income | $3,583,000 | $3,508,000 | $3,674,000 | $2,036,000 |
| % Margin | 23.6% | 24.3% | 27% | 13.7% |
| Other Income/Exp. Net | -$339,000 | -$381,000 | -$272,000 | -$370,000 |
| Pre-Tax Income | $3,244,000 | $3,127,000 | $3,402,000 | $1,666,000 |
| Tax Expense | $709,000 | $679,000 | $481,000 | $166,000 |
| Net Income | $2,533,000 | $2,450,000 | $2,916,000 | $1,500,000 |
| % Margin | 16.7% | 16.9% | 21.5% | 10.1% |
| EPS | 0.82 | 0.79 | 0.94 | 0.49 |
| % Growth | 3.8% | -16% | 91.8% | – |
| EPS Diluted | 0.81 | 0.79 | 0.94 | 0.48 |
| Weighted Avg Shares Out | 3,127,160 | 3,100,000 | 3,100,000 | 3,100,000 |
| Weighted Avg Shares Out Dil | 3,122,000 | 3,118,000 | 3,122,000 | 3,124,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $68,000 | $84,000 | $64,000 |
| Interest Expense | $349,000 | $439,000 | $349,000 | $429,000 |
| Depreciation & Amortization | $1,549,000 | $1,389,000 | $1,284,000 | $714,000 |
| EBITDA | $5,142,000 | $4,955,000 | $5,035,000 | $2,809,000 |
| % Margin | 33.8% | 34.3% | 37.1% | 18.9% |